A clinical analysis of sinonasal squamous cell carcinoma: a comparison of de novo squamous cell carcinoma and squamous cell carcinoma arising from inverted papilloma
A clinical analysis of sinonasal squamous cell carcinoma: a comparison of de novo squamous cell carcinoma and squamous cell carcinoma arising from inverted papilloma
复制标题
DOI：
10.1080/00016489.2020.1758342
复制
发表时间：
2020-05-08
影响因子：
1.4
通讯作者：
Nakagawa, Takashi
中科院分区：
文献类型：
--
作者：
Yasumatsu, Ryuji;Jiromaru, Rina;Nakagawa, Takashi
背景：鼻腔鳞状细胞癌(SCC)是一种新发或合并内翻性乳头状瘤(IP)的罕见肿瘤。目的：本研究的目的是根据鼻腔鳞状细胞癌的病因，调查和比较其肿瘤学特征和预后。材料和方法：对117例确诊为新发鳞状细胞癌或IP(IP-SCC)患者的临床资料进行回顾性分析。对10例IP-SCC进行HPV16/18DNA原位杂交和p16免疫组织化学检测。结果：在两组肿瘤中，T1、2和3型患者的3年疾病特异性生存率(DSS)均高于T4型患者。初发鳞癌患者的DSS明显好于IP-SCC患者。10例IP-SCC均未检出HPV16/18。结论和意义：初发鳞癌T4患者的DSS往往好于IP-SCC患者。由于一些患有IP-SCC的T4患者被发现患有高度侵袭性的疾病，因此应该进行仔细的治疗计划。在大多数IP-SCC病例的癌变过程中，高危HPV可能不起重要作用。
Background: Sinonasal squamous cell carcinoma (SCC) is a rare tumor arising either de novo or in association with inverted papillomas (IPs). Objectives: The aim of this study was to investigate and compare the oncological features and prognosis of patients with sinonasal SCCs based on their etiology. Material and methods: The medical records of 117 patients who had been diagnosed with de novo SCC or those arising from IP (IP-SCC) were retrospectively reviewed. In situ hybridization analyses to detect HPV 16/18DNA and p16 immunohistochemistry were also performed in 10 cases with IP-SCC. Results: The three-year disease-specific survival (DSS) rate was higher in cases with T1, 2 and 3 than in cases with T4 in both tumor groups. T4 cases with de novo SCC had a better DSS than those with IP-SCCs. HPV16/18 was not detected in any of the 10 IP-SCCs. Conclusions and significance: T4 cases with de novo SCC tended to have a better DSS than those with IP-SCC. Since some T4 patients with IP-SCC were found to have a highly aggressive disease, careful treatment planning should be performed. High-risk HPV may not play a vital role in the carcinomatous transformation of most IP-SCC cases.